← Leaderboards
Kent E Hutchison
University Of Colorado Denver
$29,753,664
Attributed
$33,360,861
Total exposure
28
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,741,409 · 29
By mechanism
R01$32,232,007 · 13
P50$8,946,580 · 2
M01$400,526 · 13
R21$162,296 · 1
Top collaborators
- Vince D Calhoun6 shared
- Angela D Bryan4 shared
- L. Cinnamon Bidwell2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Christian J Hopfer$14,204,504
- Joshua Leigh Gowin$2,091,588
- Ashley Brooks-Russell$4,251,896
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCravingGeneticCuesDesignResearch PersonnelDoseAlcohol DependenceBiologicalPharmaceutical PreparationsMediatingSamplingResponseFundingRandomizedDrinkingGenesAlcoholsPublic HealthBehavioralCannabidiolCannabinoidsClinical ResearchUnited States
Grant awards (91)
Rocky Mountain Cannabis Research Center$2,803,466
P50 · FY2025 · DA · contact PI
Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial$700,472
R01 · FY2025 · AG · contact PI
Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies$495,131
R01 · FY2025 · AA · contact PI
Administrative Core$283,016
P50 · FY2025 · DA · contact PI
Rocky Mountain Cannabis Research Center$2,803,466
P50 · FY2024 · DA · contact PI
Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial$709,313
R01 · FY2024 · AG · contact PI
Novel Approaches to Opiate Use Reduction$591,853
R01 · FY2024 · DA · contact PI
Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies$498,458
R01 · FY2024 · AA · contact PI
Administrative Core$283,016
P50 · FY2024 · DA · contact PI
Hemp-derived Cannabidiol for the treatment of cannabis use disorder in concentrate users: A double-blind placebo-controlled randomized trial$98,952
R01 · FY2024 · DA
Rocky Mountain Cannabis Research Center$2,773,616
P50 · FY2023 · DA · contact PI
Hemp-derived Cannabidiol for the treatment of cannabis use disorder in concentrate users: A double-blind placebo-controlled randomized trial$741,850
R01 · FY2023 · DA
Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial$733,468
R01 · FY2023 · AG · contact PI
Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC$650,978
R01 · FY2023 · CA
Novel Approaches to Opiate Use Reduction$620,598
R01 · FY2023 · DA · contact PI
Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies$496,806
R01 · FY2023 · AA · contact PI
Novel Approaches to Opiate Use Reduction$628,448
R01 · FY2022 · DA · contact PI
Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies$540,010
R01 · FY2022 · AA · contact PI
Novel Approaches to Opiate Use Reduction$628,179
R01 · FY2021 · DA · contact PI
Novel Approaches to Opiate Use Reduction$640,563
R01 · FY2020 · DA · contact PI
Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action$565,804
R01 · FY2020 · AA · contact PI
Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge$202,845
R01 · FY2020 · DA · contact PI
Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge$200,780
R01 · FY2020 · DA · contact PI
Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action$608,478
R01 · FY2019 · AA · contact PI
COINSTAC: Decentralized, Scalable Analysis of Loosely Coupled Data$585,151
R01 · FY2019 · DA
Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge$478,595
R01 · FY2019 · DA · contact PI
COINSTAC: decentralized, scalable analysis of loosely coupled data$649,098
R01 · FY2018 · DA
Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action$608,478
R01 · FY2018 · AA · contact PI
Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge$478,010
R01 · FY2018 · DA · contact PI
COINSTAC: decentralized, scalable analysis of loosely coupled data$282,320
R01 · FY2018 · DA
COINSTAC: decentralized, scalable analysis of loosely coupled data$655,080
R01 · FY2017 · DA
Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action$608,478
R01 · FY2017 · AA · contact PI
Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge$412,119
R01 · FY2017 · DA · contact PI
COINSTAC: decentralized, scalable analysis of loosely coupled data$680,020
R01 · FY2016 · DA
Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action$622,811
R01 · FY2016 · AA · contact PI
Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge$441,035
R01 · FY2016 · DA · contact PI
COINSTAC: decentralized, scalable analysis of loosely coupled data$727,692
R01 · FY2015 · DA
Effectiveness of Varenicline: Testing Individual Differences$698,488
R01 · FY2014 · DA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$495,636
R01 · FY2014 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$566,080
R01 · FY2013 · AA · contact PI
Effectiveness of Varenicline: Testing Individual Differences$529,658
R01 · FY2013 · DA · contact PI
Effectiveness of Varenicline: Testing Individual Differences$94,682
R01 · FY2013 · DA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$617,742
R01 · FY2012 · AA · contact PI
Effectiveness of Varenicline: Testing Individual Differences$519,055
R01 · FY2012 · DA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$624,274
R01 · FY2011 · AA · contact PI
Effectiveness of Varenicline: Testing Individual Differences$522,858
R01 · FY2011 · DA · contact PI
Sensitivity to Intravenous Ethanol: Genetic Determinants$328,062
R01 · FY2011 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$558,425
R01 · FY2010 · AA · contact PI
A New Pharmacotherapy for Alcohol Dependence: Olanzapine$547,578
R01 · FY2010 · AA · contact PI
Sensitivity to Intravenous Ethanol: Genetic Determinants$481,153
R01 · FY2010 · AA · contact PI
A NEW PHARMACOTHERAPY FOR ALCOHOL DEPENDENCE: OLANZAPINE$73,607
M01 · FY2010 · RR · contact PI
SENSITIVITY TO INTRAVENOUS ETHANOL: GENETIC DETERMINANTS$20,900
M01 · FY2010 · RR · contact PI
A New Pharmacotherapy for Alcohol Dependence: Olanzapine$554,610
R01 · FY2009 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$495,466
R01 · FY2009 · AA · contact PI
Effectiveness of Varenicline: Testing Individual Differences$487,656
R01 · FY2009 · DA · contact PI
Sensitivity to Intravenous Ethanol: Genetic Determinants$481,253
R01 · FY2009 · AA · contact PI
A NEW PHARMACOTHERAPY FOR ALCOHOL DPENDENCE: OLANZAPINE$110,793
M01 · FY2009 · RR · contact PI
A New Pharmacotherapy for Alcohol Dependence: Olanzapine$22,692
R01 · FY2009 · AA · contact PI
SENSITIVITY TO INTRAVENOUS ETHANOL: GENETIC DETERMINANTS$14,451
M01 · FY2009 · RR · contact PI
A New Pharmacotherapy for Alcohol Dependence: Olanzapine$538,897
R01 · FY2008 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$489,133
R01 · FY2008 · AA · contact PI
Sensitivity to Intravenous Ethanol: Genetic Determinants$349,586
R01 · FY2008 · AA · contact PI
Sensitivity to Intravenous Ethanol: Genetic Determinants$83,158
R01 · FY2008 · AA · contact PI
A NEW PHARMACOTHERAPY FOR ALCOHOL DPENDENCE: OLANZAPINE$4,845
M01 · FY2008 · RR · contact PI
A NEW PHARMACOTHERAPY FOR ALCOHOL DEPENDENCE$2,096
M01 · FY2008 · RR · contact PI
A New Pharmacotherapy for Alcohol Dependence: Olanzapine$409,750
R01 · FY2007 · AA · contact PI
Sensitivity to Intravenous Ethanol: Genetic Determinants$356,985
R01 · FY2007 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$355,250
R01 · FY2007 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$122,395
R01 · FY2007 · AA · contact PI
A New Pharmacotherapy for Alcohol Dependence: Olanzapine$89,292
R01 · FY2007 · AA · contact PI
GENETIC FACTORS INFLUENCING RESPONSES TO NALTREXONE$24,237
M01 · FY2007 · RR · contact PI
A NEW PHARMACOTHERAPY FOR ALCOHOL DEPENDENCE$10,099
M01 · FY2007 · RR · contact PI
New Pharmacotherapy for Alcohol Dependence: Olanzapine$521,217
R01 · FY2006 · AA · contact PI
Alcohol Dependence: Integrating Genetic & fMRI Methods$457,731
R01 · FY2006 · AA · contact PI
GENE REGULATION AND ADDITION: INVESTIGATING THE IMPACT OF SNP'S ON GENE EXPRESSI$24,136
M01 · FY2006 · RR · contact PI
GENETIC FACTORS INFLUENCING RESPONSES TO NALTREXONE$20,114
M01 · FY2006 · RR · contact PI
Alcohol Dependence: Integrating Genetic &fMRI Methods$460,318
R01 · FY2005 · AA
Progression of Craving and Addiction: Genetic Factors$294,000
R01 · FY2005 · DA
GENE REGULATION AND ADDITION: INVESTIGATING THE IMPACT OF SNP'S ON GENE EXPRESSI$20,302
M01 · FY2005 · RR
GENETIC AND ENVIRONMENTAL VULNERABILITIES TO ALCOHOL ABUSE AND DEPENDENCE$7,148
M01 · FY2005 · RR
PHARMACOLOGICAL MECHANISMS RELATED TO THE CRAVING FOR ALCOHOL$3,146
M01 · FY2005 · RR
Progression of Craving and Addiction: Genetic Factors$294,000
R01 · FY2004 · DA
Pharmacological mechanisms related to alcohol craving$39,493
M01 · FY2004 · RR
Genetic &Environmental Vulnerabilities to Alcohol Abuse$25,159
M01 · FY2004 · RR
Progression of Craving and Addiction: Genetic Factors$294,000
R01 · FY2003 · DA
Progression of Craving and Addiction: Genetic Factors$294,000
R01 · FY2002 · DA
STARTLE REFLEX--TESTING ALCOHOL PATIENTS AND TREATMENTS$116,245
R01 · FY2002 · AA
Progression of Craving and Addiction: Genetic Factors$290,216
R01 · FY2001 · DA
STARTLE REFLEX--TESTING ALCOHOL PATIENTS AND TREATMENTS$113,302
R01 · FY2001 · AA
PSYCHOPHYSIOLOGICAL AND BEHAVIORAL MECHANISMS OF SMOKING$162,296
R21 · FY2000 · CA
STARTLE REFLEX--TESTING ALCOHOL PATIENTS AND TREATMENTS$95,291
R01 · FY2000 · AA